Medical marijuana has demonstrated its potential effectiveness in trials and is currently being used legally in medical settings in different countries across the globe as a therapeutic for conditions that range from its use as an appetite stimulant for patients with wasting syndrome usually associated with AIDS to palliative care for cancer.
In Europe, some nations permit the use of medicinal products that contain CBD (cannabidiol) while others do not allow marijuana product manufacture but allow importation of marijuana products. Various countries across Europe have already legalized medical cannabis and have established legislations that regulate its use. They include Portugal, Poland and the United Kingdom. However, there are other countries, also in Europe, where medical marijuana is strictly prohibited and so is its sale, purchase or use. These countries include Albania, Belgium, Latvia and Sweden.
In the middle, there exist countries that allow the supply of some marijuana products under specific conditions or those that are working on making it legal. A good example of such would be France. Earlier in January of this year, France administered a questionnaire on marijuana legalization. The main objective of the exercise was to legitimize the content of a proposal on adult-use marijuana that the French Parliament was working on, as well as ease concerns over possible reform ahead of next year’s elections.
The questionnaire asked respondents whether they believed that the present system that is in place was effective in the fight against the illicit use of marijuana as well as marijuana trafficking.
Last week, the government of France launched a two-year countrywide experiment with medical marijuana. If the program, which was approved by parliament in 2019, is successful, the country may end up legalizing the plant for medical use.
In a statement, the Health Ministry noted that roughly 3,000 patients across France will be administered with medical marijuana treatments. During this period, their health will be observed and recorded by the national medicines observer. The first prescription was given on Friday in the Southern France Clermont-Ferrand University Hospital.
The Health Ministry also revealed that the objective of the experiment is to collect as much data as possible about the safety and effectiveness of therapeutic cannabis as well as prepare the logistical circuits for distribution in future.
While the eligibility criteria has yet to be made clear, those who will be allowed to participate in the program include individuals in palliative care, individuals suffering from some forms of epilepsy, individuals with nerve pain that cannot be managed or treated using other methods and patients suffering from various types of cancer.
The patients who take part in the medical marijuana experiment in France will be pleased to learn that the data analytics and IoT sectors are active in the plant medicine industry, as exemplified by the remote dose-measuring device produced by RYAH Group Inc.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://cnw.fm/RYAH
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
